WILSON GLYNN 4
4 · Cadrenal Therapeutics, Inc. · Filed Jan 24, 2023
Insider Transaction Report
Form 4
WILSON GLYNN
Director
Transactions
- Conversion
Common Stock
2023-01-24+50,000→ 50,000 total - Conversion
Convertible Promissory Note
2023-01-24−50,000→ 0 totalExercise: $1.00→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Dr. Wilson was issued 50,000 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $50,000, based on a conversion price of $1.00 per share.